News Briefs: CMS to Hire “Small Army” of Drug Pricing Staff

After Michelle McMurray-Heath, M.D., resigned from her position as president and CEO of the Biotechnology Innovation Organization, the major industry trade group said on Oct. 11 that Rachel King, co-founder and former CEO of GlycoMimetics, Inc., agreed to serve in those roles on an interim basis while BIO searches for a permanent successor. Before her departure, McMurray-Heath was on leave following disagreements with some board members over whether BIO should engage on social issues not directly connected to health care policy, which the molecular immunologist opposed, The Wall Street Journal reported. Her exit also comes in the wake of Congress’ passage of major drug pricing reforms as part of the Inflation Reduction Act, representing a rare defeat for the powerful pharma lobby.

© 2022 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-viewing-news-update-journalism-headline-on-a-laptop
November 22

News Briefs: Optum to Include Humira Biosimilars in Formulary

READ MORE
business-meeting
November 22

Customer Satisfaction With PBMs Drops to a Three-Year Low, Study Reports

READ MORE
business-meeting
November 22

End of COVID Bump, Negative News May Have Dented PBM Satisfaction

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today